No Data
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating, Maintains Target Price $1.78
Analysts Have Conflicting Sentiments on These Healthcare Companies: Passage Bio (PASG), Phreesia (PHR) and Esperion (ESPR)
Merck Oral PCSK9 Enlicitide Shows Improved Cholesterol Lowering Vs. Non-statins
Esperion Showcases New Data From CLEAR Outcomes Highlighting Value of NEXLETOL (Bempedoic Acid) at the American College of Cardiology's Annual Scientific Session 2026
CH16 : ESPR is not for the faint hearted